New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
09:04 EDTBWLD, AMGN, ZLTQ, GPRE, X, IACI, ESRX, AEGR, SODA, S, UAL, DWA, TWTR, GRMN, HESOn The Fly: Pre-market Movers
HIGHER: Twitter (TWTR), up 25% after better than expected Q2 earnings results, upgraded at UBS, BofA Merrill Lynch and CRT Capital... Hess (HES), up 4.6% after reporting better than expected Q2 adjusted EPS, boosting its share buyback and announcing its intention to pursue the formation and initial public offering of a master limited partnership... United Continental (UAL), up 2.8% following upgrade to Overweight at JPMorgan. UP AFTER EARNINGS: Sprint (S), up 3.3%... Garmin (GRMN), up 9.4%... ZELTIQ (ZLTQ), up 24%... Aegerion (AEGR), up 14%... U.S. Steel (X), up 16%... Express Scripts (ESRX), up 3%... Amgen (AMGN), up 4.6%... SodaStream (SODA), up 8%. LOWER: DreamWorks Animation (DWA), down 11.8% after worse than expected Q2 loss, disclosing SEC investigating 'Turbo' writedown... IAC Interactive (IACI), down 3.4% after Q2 results miss expectations, Tutor.com unit acquires The Princeton Review. DOWN AFTER EARNINGS: Buffalo Wild Wings (BWLD), down 8.4%... Green Plains (GPRE), down 3.3%.
News For TWTR;S;HES;DWA;SODA;GRMN;UAL;ZLTQ;AEGR;X;AMGN;ESRX;GPRE;BWLD;IACI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
December 9, 2014
09:38 EDTTWTR, XActive equity options trading
Subscribe for More Information
09:21 EDTUALOn The Fly: Pre-market Movers
UP AFTER EARNINGS: AutoZone (AZO), up 3.8%... Burlington Stores (BURL), up 3.3%. ALSO HIGHER: bluebird bio (BLUE), up 56.5% after price target raised at Piper Jaffray and SunTrust... Camtek (CAMT), up 6.7% after being awarded a $2.8M order from a semiconductor manufacturer... PDC Energy (PDCE), up 5.8% after providing fiscal 2015 production guidance... Mast Therapeutics (MSTX), up 3.1% after reporting that it will begin recruiting patients for MST-188 study in first half of fiscal 2015... Idera Pharmaceuticals (IDRA), up 1.4% after announcing data for its lead product candidate, IMO-8400. DOWN AFTER EARNINGS: UTi Worldwide (UTIW), down 10.8%... CONN'S (CONN), down 35.9% after reporting third quarter results, withdrawing fiscal 2015 guidance, stating that there is no timetable set for completion of strategic alternatives, and announcing the departure of its CFO. ALSO LOWER: Apple (AAPL), down 1.6% after Pacific Crest says that weak iPad demand could cause Apple to miss estimates and following a Wall Street Journal report that a judge denied Apple's efforts to throw out iPod pricing lawsuit... Allied Nevada Gold (ANV), down 30.1% after announcing pricing of common stock and warrant offering... United Continental (UAL), down 2.7% after reporting November traffic.
07:44 EDTAMGNAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
06:03 EDTDWADreamWorks Animation downgraded to Sell from Hold at Topeka
05:40 EDTAMGNAmgen presents new BLINCYTO Phase 2 study data at ASH meeting
Amgen announced that new data from a pivotal Phase 2 study evaluating BLINCYTO for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, or ALL was presented at the 56th American Society of Hematology, or ASH, Annual Meeting and Exposition. In one analysis from the '211 study, 40% of patients treated with BLINCYTO who achieved a complete remission, or CR, or complete remission with partial hematologic recovery, or CRh, were enabled to proceed to allogeneic hematopoietic stem cell transplant, or HSCT. Additionally, a secondary analysis from the study found that 82% of patients who had a CR or CRh also had a minimal residual disease, or MRD, response, a measure used to predict disease recurrence in patients with ALL. In one analysis of the '211 study, 40% of patients treated with BLINCYTO who achieved a CR or CRh were enabled to proceed to HSCT, including both patients who had received prior HSCT and patients who had not received prior HSCT. A secondary analysis of the study demonstrated that, among patients receiving BLINCYTO who had a CR or CRh and had evaluable MRD data, 82% had an MRD response, with 70% of those patients achieving a complete MRD response. Median overall survival was longer among patients who had a CR or CRh and an MRD response compared to patients who didn't have an MRD response.
December 8, 2014
16:26 EDTUALUnited Continental November consolidated traffic down 0.3%
Subscribe for More Information
16:24 EDTAMGNAmgen initiates new combination trial for talimogene laherparepvec with KEYTRUDA
Subscribe for More Information
14:56 EDTSMDC Partners climbs for third day after making announcement on CRM unit
Subscribe for More Information
14:24 EDTTWTRRumor: Twitter moves off lows amid speculation Apple may take a stake
Subscribe for More Information
13:38 EDTTWTRTwitter breaks to lows of the day, levels to watch
The shares are down over 6.7% to $35.89 at time of writing. Resistance is now at former support at $36.38. Support is now at $35.06.
11:30 EDTESRXLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
11:21 EDTTWTRTwitter volatility low as shares pullback to four-month low
Twitter December weekly call option implied volatility is at 51, December is at 46, January at 43; compared to its 26-week average of 54 according to Track Data, suggesting decreasing price movement
10:20 EDTDWAOptions with decreasing implied volatility
Subscribe for More Information
10:16 EDTTWTRTwitter falls to session lows, levels to watch
Subscribe for More Information
09:09 EDTAMGNAmgen announces FDA approval for XGEVA
Amgen announced that the FDA has approved a new indication for XGEVA for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. XGEVA was approved and granted Orphan Drug Designation by the FDA, which is reserved for drugs that are intended for the treatment of rare diseases affecting fewer than 200,000 people in the U.S. HCM is a serious complication in patients with advanced cancer, including those with hematologic malignancies, and indicates poor prognosis.1,2 The condition results from cancer-driven increases in bone resorption, and if untreated, can lead to renal failure, progressive mental impairment, coma and death. The approval of XGEVA is based on positive results from an open-label, single-arm study, which enrolled patients with advanced cancer and persistent hypercalcemia after recent bisphosphonate treatment. The primary endpoint was the proportion of patients with a response, defined as albumin-corrected serum calcium <11.5 mg/dLwithin 10 days after the first dose of XGEVA. Secondary endpoints included the proportion of patients who experienced a complete response (defined as CSC <10.8 mg/dL by day 10, time to response and response duration. The study achieved its primary endpoint with a response rate at day 10 of 63.6 percent in the 33 patients evaluated. The overall complete response rate was 63.6 percent. The estimated median time to response was nine days, and the median duration of response was 104 days.4,5
09:09 EDTAMGNAmgen announces FDA approval for XGEVA
Subscribe for More Information
07:26 EDTZLTQLeerink to hold a tour
Subscribe for More Information
06:40 EDTIACIIAC looks to sell majority stake in CollegeHumor, Fortune reports
IAC is looking to sell entertainment website CollegeHumor for around $100M, Fortune reports, citing sources. IAC bought a majority stake in the entertainment website eight years ago for around $20M. Reference Link
06:00 EDTTWTRTwitter's former head of product leaving company, Re/code reports
Daniel Graf, who was replaced by Kevin Weil as head of product last month, is leaving the company, Re/code reports. Reference Link
05:42 EDTAMGNSandoz Phase III data shows filgrastim has similar safety, efficacy as NEUPOGEN
Sandoz, a Novartis (NVS) company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's (AMGN) NEUPOGEN in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy. The study also showed that repeated switching at each cycle between the investigational biosimilar and the originator filgrastim showed no impact on efficacy, safety or immunogenicity. The PIONEER study was a Phase III study designed to compare the efficacy and safety of the investigational biosimilar and the reference product with respect to mean duration of severe neutropenia following Cycle 1 chemotherapy. PIONEER was a randomized, double-blind, four-group, multi-center non-inferiority trial conducted at 27 centers. The trial randomized 218 breast cancer patients receiving neoadjuvant myelosuppressive chemotherapy.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use